Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1381-1390

  Chung, Victoria ^a   Carroll, Anthony R ^a   Gray, Norman M ^a   Parry, Nigel R ^a   Thommes, Pia A ^a   Viner, K Claire ^a   D'Souza, Eric A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE; POLYPROTEIN; PROTEINASE; PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CERCOPITHECIDAE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; WESTERN BLOTTING;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPACIVIRUS; HUMANS; LACTAMS; MICROBIAL SENSITIVITY TESTS; PROTEASE INHIBITORS; REPLICON; VACCINIA VIRUS; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 16244397349     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1381-1390.2005     Document Type: Article

References (35)

1. Andrews, D. M., S. J. Carey, H. Chaignot, B. A. Coomber, N. M. Gray, S. L. Hind, P. S. Jones, G. Mills, J. E. Robinson, and M. J. Slater. 2002. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease. Org. Lett. 4:4475-4478.
2. Andrews, D. M., H. M. Chaignot, B. A. Coomber, A. C. Good, S. L. Hind, M. R. Johnson, P. S. Jones, G. Mills, J. E. Robinson, T. Skarzynski, M. J. Slater, and D. O. Somers. 2002. Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimisation of P3 and P4 substituents. Org. Lett. 4:4479-4482.
3. Andrews, D. M., P. S. Jones, G. Mills, S. L. Hind, M. J. Slater, N. Trivedi, and K. J. Wareing. 2003. Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. Bioorg. Med. Chem. Lett. 13:1657-1660.
4. Andrews, D. M., H. M. Chaignot, B. A. Coomber, M. D. Dowle, S. L. Hind, M. R. Johnson, P. S. Jones, G. Mills, A. Patikis, T. J. Pateman, J. E. Robinson, M. J. Slater, and N. Trivedi. 2003. The design of potent, non-peptidic inhibitors of hepatitis C protease. Eur. J. Med. Chem. 38:339-343.
5. Andrews, D. M., M. C. Barnes, M. D. Dowle, S. L. Hind, M. R. Johnson, P. S. Jones, G. Mills, A. Patikis, T. J. Pateman, T. J. Redfern, J. E. Robinson, M. J. Slater, and N. Trivedi. 2003. Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimisation of inhibitors of hepatitis C virus NS3/4A protease. Org. Lett. 5:4631-4634.
6. Bartenschlager, R. 2002. Hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug Discov. 1:911-916.
7. Bartenschlager, R., L. Ahlborn-Laake, K. Yasargil, J. Mous, and H. Jacobsen. 1995. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J. Virol. 69:198-205.
8. Beard, M. R., G. Abell, M. Honda, A. Carroll, M. Gartland, B. Clarke, K. Suzuki, R. Lanford, D. V. Sangar, and S. M. Lemon. 1999. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology 30:316-324.
9. Boulant, S., M. Becchi, F. Penin, and J.-P. Lavergne. 2003. Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from genotype 1b. J. Biol. Chem. 278:45785-45792.
10. Cho, Y. G., H. S. Moon, and Y. C. Sung. 1997. Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity. J. Virol. Methods 65:201-207.
11. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a Hood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
12. De Francesco, R., and C. Steinkühler. 2000. Structure and function of the hepatitis C virus NS3-NS4A serine protease. Curr. Top. Microbiol. Immunol. 242:149-169.
13. De Francesco, R., P. Neddermann, L. Tomei, C. Steinkühler, P. Gallinari, and A. Folgori. 2000. Biochemical and immunologic properties of the non-structural proteins of the hepatitis C virus: implications for the development of antiviral agents and vaccines. Semin. Liver Dis. 20:69-83.
14. De Francesco, R., L. Tomei, S. Altamura, V. Summa, and G. Migliaccio. 2003. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antivir. Res. 58:1-16.
15. Falkner, F. O., and B. Moss. 1988. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 62:1849-1854.
16. Fukuda, K., D. Vishnuvardhan, S. Sekiya, J. Hwang, N. Kakiuchi, K. Taira, K. Shimotohno, P. K. R. Kumar, and S. Nishikawa. 2000. Isolation and characterisation of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur. J. Biochem. 267:3685-3694.
17. Hahm, B., S. H. Back, T. G. Lee, E. Wimmer, and S. K. Jang. 1996. Generation of a novel poliovirus with a requirement of hepatitis C virus protease activity. Virology 226:318-326.
18. Kolykhalov, A. A., K. Mihalik, S. M. Feinstone, and C. M. Rice. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for replication in vivo. J. Virol. 74:2046-2051.
19. Kwong, A. D., J. L. Kim, G. Rao, D. Lipovsek, and S. A. Raybuck. 1998. Hepatitis C virus NS3/4A protease. Antivir. Res. 40:1-18.
20. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bös, D. R. Cameron, M. Cartier, M. G. Cordingley, A.-M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagacé, S. R. LaPlante, H. Narjes, M-A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C.-L. Yong, and M. Linàs-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
21. Lauer, G. M., and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52.
22. Lee, J. C., Y. F. Shih, S. P. Hsu, T. Y. Chang, L. H. Chen, and J. T. A. Hsu. 2003. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal. Biochem. 316:152-70.
23. Lohmann, V., F. Korner, J.-O. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
24. Macdonald, S. J., M. D. Dowle, L. A. Harrison, P. Shah, M. R. Johnson, G. G. Inglis, G. D. Clarke, R. A. Smith, D. Humphreys, C. R. Molloy, A. Amour, M. Dixon, G. Murkitt, R. E. Goodward, T. Padfield, T. Skarzynski, O. M. Singh, K. A. Kumar, G. Fleetwood, S. T. Hodgson, G. W. Hardy, and H. Finch. 2001. The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase-GW311616A a development candidate. Bioorg. Med. Chem. Lett. 11:895-898.
25. McPhee, F., K. S. Yeung, A. C. Good, and N. A. Meanwell. 2003. Hepatitis C virus NS3 serine protease as a drug discovery target. Drug Future 28:465-488.
26. Moradpour, D., V. Brass, R. Gosert, B. Wölk, and H. E. Blum. 2002. Hepatitis C: molecular virology and antiviral targets. Trends Mol. Med. 8:476-482.
27. Moss, B., O. Elroy-Stein, T. Mizukami, W. A. Alexander, and T. R. Fuerst. 1990. New mammalian expression vectors. Nature 348:91-92.
28. Narjes, F., U. Koch, and C. Steinkühler. 2003. Recent developments in the discovery of hepatitis C virus serine protease inhibitors-towards a new class of antiviral agents? Expert Opin. Investig. Drugs 12:153-163.
29. Pacini, L., L. Bartholomew, A. Vitelli, and G. Migliaccio. 2004. Reporter substrates for assessing the activity of the hepatitis C virus NS3-4A serine protease in living cells. Anal. Biochem. 331:46-59.
30. Rice, C. M. 1996. Flaviviridae: the viruses and their replication, p. 931-959. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. 3rd ed. Lippincott-Raven, Philadelphia, Pa.
31. Slater, M. J., D. M. Andrews, G. Baker, S. S. Bethell, S. J. Carey, H. M. Chaignot, B. Clarke, B. Coomber, M. Ellis, A. Good, N. M. Gray, G. Hardy, P. S. Jones, G. Mills, and J. E. Robinson. 2002. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. Bioorg. Med. Chem. Lett. 12:3359-3362.
32. Slater, M. J., E. M. Amphlett, D. M. Andrews, P. Bamborough, S. J. Carey, M. R. Johnson, P. S. Jones, G. Mills, N. R. Parry, D. O. Somers, A. J. Stewart, and T. Skarzynski. 2003. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease. Org. Lett. 5:4627-4630.
33. Tanji, Y., M. Hijikata, S. Satoh, T. Kaneko, and K. Shimotohno. 1995. Hepatitis C virus-encoded non-structural protein NS4A has versatile functions in viral protein processing. J. Virol. 69:1575-1581.
34. Tomei, L., C. Failla, E. Santolini, R. DeFrancesco, and N. La Monica. 1993. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67:4017-4026.
35. Wölk, B., D. Sansonno, H.-G. Kräusslich, F. Dammacco, C. M. Rice, H. E. Blum, and D. Moradpour. 2000. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 74:2293-2304.